Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter
  • Published:

Oncogenic pathway signatures in human cancers as a guide to targeted therapies


The development of an oncogenic state is a complex process involving the accumulation of multiple independent mutations that lead to deregulation of cell signalling pathways central to the control of cell growth and cell fate1,2,3. The ability to define cancer subtypes, recurrence of disease and response to specific therapies using DNA microarray-based gene expression signatures has been demonstrated in multiple studies4. Various studies have also demonstrated the potential for using gene expression profiles for the analysis of oncogenic pathways5,6,7,8,9,10,11. Here we show that gene expression signatures can be identified that reflect the activation status of several oncogenic pathways. When evaluated in several large collections of human cancers, these gene expression signatures identify patterns of pathway deregulation in tumours and clinically relevant associations with disease outcomes. Combining signature-based predictions across several pathways identifies coordinated patterns of pathway deregulation that distinguish between specific cancers and tumour subtypes. Clustering tumours based on pathway signatures further defines prognosis in respective patient subsets, demonstrating that patterns of oncogenic pathway deregulation underlie the development of the oncogenic phenotype and reflect the biology and outcome of specific cancers. Predictions of pathway deregulation in cancer cell lines are also shown to predict the sensitivity to therapeutic agents that target components of the pathway. Linking pathway deregulation with sensitivity to therapeutics that target components of the pathway provides an opportunity to make use of these oncogenic pathway signatures to guide the use of targeted therapeutics.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Gene expression patterns that predict oncogenic pathway deregulation.
Figure 2: Validation of pathway predictions in tumours.
Figure 3: Patterns of pathway deregulation in human cancers.
Figure 4: Pathway deregulation in breast cancer cell lines predicts drug sensitivity.

Similar content being viewed by others


  1. Fearon, E. R. & Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell 17, 671–674 (1990)

    Google Scholar 

  2. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000)

    Article  CAS  PubMed  Google Scholar 

  3. Sherr, C. J. Cancer cell cycles. Science 274, 1672–1677 (1996)

    Article  CAS  ADS  PubMed  Google Scholar 

  4. Ramaswamy, S. & Golub, T. R. DNA microarrays in clinical oncology. J. Clin. Oncol. 20, 1932–1941 (2002)

    Article  CAS  PubMed  Google Scholar 

  5. Lamb, J. et al. A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell 114, 323–334 (2003)

    Article  CAS  PubMed  Google Scholar 

  6. Huang, E. et al. Gene expression phenotypic models that predict the activity of oncogenic pathways. Nature Genet. 34, 226–230 (2003)

    Article  CAS  PubMed  Google Scholar 

  7. Black, E. P. et al. Distinct gene expression phenotypes of cells lacking Rb and Rb family members. Cancer Res. 63, 3716–3723 (2003)

    CAS  PubMed  Google Scholar 

  8. Segal, E., Friedman, N., Koller, D. & Regev, A. A module map showing conditional activity of expression modules in cancer. Nature Genet. 36, 1090–1098 (2004)

    Article  CAS  PubMed  Google Scholar 

  9. Rhodes, D. R. et al. Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc. Natl Acad. Sci. USA 101, 9309–9314 (2004)

    Article  CAS  ADS  PubMed  PubMed Central  Google Scholar 

  10. Ramaswamy, S., Ross, K. N., Lander, E. S. & Golub, T. R. A molecular signature of metastasis in primary solid tumors. Nature Genet. 33, 49–54 (2003)

    Article  CAS  PubMed  Google Scholar 

  11. Mootha, V. K. et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nature Genet. 34, 267–273 (2003)

    Article  CAS  ADS  PubMed  Google Scholar 

  12. West, M. et al. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc. Natl Acad. Sci. USA 98, 11462–11467 (2001)

    Article  CAS  ADS  PubMed  PubMed Central  Google Scholar 

  13. D'Crus, C. M. et al. c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nature Med. 7, 235–239 (2001)

    Article  Google Scholar 

  14. Sweet-Cordero, A. et al. An oncogenic KRAS2 expression signature identified by cross-species gene expression analysis. Nature Genet. 37, 48–54 (2005)

    Article  CAS  PubMed  Google Scholar 

  15. Rodenhuis, S. et al. Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study. J. Clin. Oncol. 15, 285–291 (1997)

    Article  CAS  PubMed  Google Scholar 

  16. Salgia, R. & Skarin, A. T. Molecular abnormalitities in lung cancer. J. Clin. Oncol. 16, 1207–1217 (1998)

    Article  CAS  PubMed  Google Scholar 

  17. Cory, A. H. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun. 3, 207–212 (1991)

    Article  CAS  PubMed  Google Scholar 

  18. Riss, T. L. & Moravec, R. A. Comparison of MTT, Xtt, and a novel tetrazolium compound for MTS for in vitro proliferation and chemosensitivity assays. Mol. Biol. Cell 3, 184a (1992)

    Google Scholar 

  19. Stampfer, M. R. & Yaswen, P. Culture systems for study of human mammary epithelial cell proliferation, differentiation, and transformation. Cancer Surv. 18, 7–34 (1993)

    CAS  PubMed  Google Scholar 

  20. Huang, E. et al. Gene expression predictors of breast cancer outcomes. Lancet 361, 1590–1596 (2003)

    Article  CAS  PubMed  Google Scholar 

  21. Irizarry, R. A. et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics (in the press)

  22. Bolstad, B. M., Irizarry, R. A., Astrand, M. & Speed, T. P. A comparison of normalizaton methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19, 185–193 (2003)

    Article  CAS  PubMed  Google Scholar 

  23. Eisen, M. B., Spellman, P. T., Brown, P. O. & Botstein, D. Cluster analysis and display of genome-wide expression patterns. Proc. Natl Acad. Sci. 95, 14863–14868 (1998)

    Article  CAS  ADS  PubMed  PubMed Central  Google Scholar 

  24. Mitsudomi, T. et al. Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene 6, 1353–1362 (1991)

    CAS  PubMed  Google Scholar 

Download references


We are grateful to P. Bild for the inspiration to pursue this research. We also thank K. Shianna, J. Freedman, S. Mori, L. Jakoi and K. Culler for their assistance. A.H.B. has been supported by an AACR-Anna D. Barker Fellowship and an ACS Postdoctoral Fellowship. This work was supported by grants from the NIH (to J.R.N.). Author Contributions A.H.B. was responsible for all experimental work and computational data analysis. A.H.B. and J.R.N. were responsible for project planning and data analysis. G.Y., J.T.C. and Q.W. were responsible for generation of specialized computer programs used in these studies. H.K.D. and A.P. provided intellectual input and data management support. D.C. and M.-B.J. provided technical support for experiments. M.W. was responsible for conception of the statistical approach and intellectual input. A.B., J.M.L., J.R.M., J.A.O. and D.H. were responsible for the development of clinical resources used in the study.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Joseph R. Nevins.

Ethics declarations

Competing interests

The GEO accession numbers for the datasets are: GSE3156, breast cancer cell lines; GSE3158, mouse tumour data set; GSE3151, oncogene signature data set; GSE3141, lung cancer data set; GSE3143, breast cancer data set; GSE3149, ovarian cancer data set. Reprints and permissions information is available at The authors declare no competing financial interests.

Supplementary information

Supplementary Table 1

Genes that predict pathway deregulation. (PDF 89 kb)

Supplementary Table 2

Ras mutation status in NSCLC samples. (PDF 39 kb)

Supplementary Table 3

Characteristics of breast cancer cell lines. (PDF 53 kb)

Supplementary Figure 1

Biochemical assays of pathway activation. (PDF 190 kb)

Supplementary Figure 2

Gene expression patterns that predict oncogenic pathway deregulation. (PDF 506 kb)

Supplementary Figure 3

Validation of pathway predictions in tumors. (PDF 300 kb)

Supplementary Figure 4

Kaplan-Meier survival analysis for cancer patients based on individual pathway predictions for the tumor dataset. (PDF 2243 kb)

Supplementary Figure 5

Assays for pathway activities in breast cancer cell lines. (PDF 206 kb)

Supplementary Figure 6

Relationship of drug sensitivity to predictions of untargeted pathways. (PDF 551 kb)

Supplementary Methods

This file contains a more detailed materials and methods description. (DOC 38 kb)

Supplementary Legends

Legends to accompany the above Supplementary Figures and Supplementary Tables. (DOC 28 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bild, A., Yao, G., Chang, J. et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439, 353–357 (2006).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing